How to Build a Scalable QMS from Clinic to Commercial

Let’s be honest. When you are trying to keep pace with development timelines, balance vendor oversight, and prepare for tech transfer, building or expanding a fit-for-purpose QMS might not feel urgent. Here is the catch: regulatory agencies will expect you to prove you were in control all along. If you delay building a scalable QMS, you are not just risking delays at commercialization, you are gambling with your entire program.

At Kymanox, we have supported countless innovators in the life sciences, including pharmaceutical, biotech, combination products, medical device, In-Vitro Diagnostics (IVDs), and beyond, and we have seen this pattern too often: a patchwork of reactive and lite Standard Operating Procedures (SOPs), some of the supporting product development documents from the Contract Development and Manufacturing Organization (CDMO), and a lot of hope. That approach might work short-term, but it won’t hold up when regulators come calling for an inspection or even more important, the Pre-Approval Inspection (PAI).

So, let’s rethink the QMS, which is less like a mountain to climb and more like a framework that grows with you.

Industry Standard Frameworks for Quality

To build a scalable QMS, early-phase companies must ground their quality systems in globally recognized best practices and data integrity frameworks, which include:

Core “Good Practices” (GxP):

• GLP – Good Laboratory Practices
• GCP – Good Clinical Practices
• GMP – Good Manufacturing Practices

Then, when nearing commercial readiness:

• GDP – Good Distribution Practices
• GVP – Good Pharmacovigilance Practices

These best practices are backed by ALCOA++ principles, a data integrity framework that ensures every record is:

• Attributable, Legible, Contemporaneous, Original, Accurate
• And also: Complete, Consistent, Enduring, Available, and Traceable

At the heart of it all is SISPQ (Safety, Identity, Strength, Purity, and Quality). Each component of SISPQ ensures that your product meets both regulatory and therapeutic expectations:

• Safety – Protects patients from harm and unexpected side effects
• Identity – Verifies the product is what the label claims
• Strength – Confirms correct dosing
• Purity – Eliminates harmful impurities or degradation products
• Quality – Ensures all regulatory and performance standards are consistency met

These attributes should guide everything from product development and process design to quality system development and documentation strategy.

With those industry best practices in mind, let’s talk about why phase-appropriate quality isn’t just about compliance, it’s about scalability.

Why Phase-Appropriate Quality Matters

A scalable QMS is not just a regulatory requirement, it is a strategic enabler. It should support:

• Early-phase flexibility (lean documentation, easy document repository, critical controls, right-sized for your organization, and speed to the clinic)
• Late-phase rigor (design and development history, risk management, supplier controls, and preparation of regulatory filing)
• Commercial readiness (batch disposition, complaint handling, inspection readiness, long term eQMS solutions, and continuous improvement)

It is not about building more—It is about building smart.

The foundation of this approach lies in Quality by Design (QbD) and SISPQ principles, embodied at every stage. These are supported by ALCOA++ data integrity standards and industry best practices (e.g., GMP, GLP, GCP, GDP, GVP).

Common Pitfalls We See

1. Overcomplicating too soon – Your CDMO’s QMS may be robust, but it is not yours. Regulatory agencies want to see the Sponsor’s quality oversight in action. Relying solely on a partner’s QMS can leave you exposed and has led to significant Agency actions including Warning Letters. Thorough audit qualification of suppliers and a true understanding of a QMS scaled to your company will move you towards overall compliance.
2. Copying the CDMO’s QMS – Many teams defer quality investments until they “really need it.” Supplier qualification, batch release, tech transfer, validation, and regulatory submission all rely on documentation that begins in earlier in the development cycle. Furthermore, earlier Phases require a level of QMS to govern those studies. Consult a regulatory expert to identify your applicable QMS needs.
3. Delaying until Phase 3 – Conversely, adopting a massive enterprise QMS platform when you are still running one trial site is like using a freight truck to deliver a pizza. You need flexibility, not bureaucracy. There are much simpler and lean solutions you can put in place.

Navigating GMP and QMS Evolution

As products progress through development phases, the regulatory expectations for QMS and GMP practices shift dramatically. Companies must transition from minimal early-phase controls to a fully compliant, validated system that supports commercial distribution and market oversight.

Common Late-Phase Additions:

• Technology transfer documentation
• Detailed process validation protocols
• Product and material specifications
• Vendor qualification and audit management

Without a clear plan, these challenges can cause compliance gaps or costly delays.

Read our recent article: “FDA QMSR Alignment to ISO 13485“

You Do Not Have to Do It Alone

This is where strategic partnerships shine. At Kymanox, we do not just hand you SOPs, we help you build a QMS foundation aligned with your product, your phase, and your business strategy. We’ve supported everything from creating a QMS from the very beginning to commercial ready, implementing various electronic-QMS software (eQMS) and administration, acting as the client designated quality representative and department, IND-enabling studies, clinical site qualification, regulatory meetings, product and process development, design controls and design history files (now importantly aligned with the new Quality Management System Regulation (QMSR) regulations), process validation and design validation, to Biologics License Application/Marketing Authorization Application (BLA/MAA) submissions, Investigational New Drug (IND) and New Drug Authorization (NDA) submissions, and 510k submissions, ensuring your quality system scales with you.

Whether you’re developing a gene therapy, auto-injector, IVD, or advanced biologic, quality doesn’t have to be a bottleneck. Done right, it becomes your bridge from innovation to market….Why? Because patients deserve better.